New York, NY (PRWEB) June 25, 2014
Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) that allege the antipsychotic drug caused men and boys to develop gynecomastia, or male breast growth, continue to mount in courts around the U.S., Bernstein Liebhard LLP reports. On June 12, 2014, a 24-year-old California man filed suit against Johnson & Johnson and its Janssen Pharmaceutical unit alleging his use of Risperdal caused gynecomastia so severe that he was required to undergo a double mastectomy. The complaint, which is now pending in U.S. District Court, Northern District of California, alleges that in addition to pain and physical injuries, the Plaintiff also suffered severe psychological damage due to his enlarged breasts. (Case No. 3:14-cv-02739)
“Our Firm is representing a number of clients whose experience with this medication echo the allegations put forth in the California Risperdal lawsuit,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.
Risperdal Gynecomastia Litigation
Risperdal is an atypical antipsychotic drug that is approved by the U.S. Food & Drug Administration (FDA) to treat adult and adolescent schizophrenia, bipolar disorder in adults and children ages 10-to-17, and irritability in children (5-to-16 years of age) with autistic disorder.* Recent research also indicates that off- label use of Risperdal to treat ADHD is on the rise.**
According to court documents, hundreds of Risperdal lawsuits have been filed in a mass tort litigation currently underway in Pennsylvania’s Philadelphia Court of Common Pleas, many of which involve gynecomastia allegations. Among other things, the complaints accuse Johnson & Johnson and Janssen of concealing the association between Risperdal and male breast growth, and of improperly marketing the drug for off-label use in children. (In Re: Risperdal Litigation, Case Number 100300296).
On November 4th, the U.S. Department of Justice announced that Johnson & Johnson and Janssen had agreed to pay $2.5 million to resolve criminal and civil charges stemming from their marketing of Risperdal and other drugs. Among other things, federal prosecutors had alleged that the companies marketed Risperdal for pediatric uses long before it was approved for such indications in 2006. According to court documents filed in the case, the Justice Department had also charged that the company concealed side effects associated with the medication, including an association between Risperdal and male breast growth. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Alleged victims of Risperdal and gynecomastia may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
*http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, Risperdal Prescribing Information, FDA, 2009
**health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com